Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

It Was Shkreli's Show, But Pharma Was On Trial

This article was originally published in Scrip

Executive Summary

The House Oversight and Government Reform Committee hearing on drug prices was the hottest spot in a very damp and cold Washington on Feb. 4 and former Turing Pharmaceutical Inc. CEO Martin Shkreli gave lawmakers and the overflow-crowd in attendance what they were anticipating: Several big smirky smiles, a lot of eye rolling and a refusal to testify – citing his "Act of Production Privilege" under the Fifth Amendment to the US Constitution at the advice of his counsel.

You may also be interested in...



Senate Drug Pricing Hearing Looms As Unparalleled Event For Pharma

From Vioxx to EpiPen, industry has been called in to testify before Congress on a range of issues. But with seven big pharma leaders having accepted the Senate Finance Committee's invitation Feb. 26, the stage is set for some exceptional political theater.

Senate Drug Pricing Hearing Looms As Unparalleled Event For Pharma

From Vioxx to EpiPen, industry has been called in to testify before Congress on a range of issues. But with seven big pharma leaders having accepted the Senate Finance Committee's invitation Feb. 26, the stage is set for some exceptional political theater.

How Many Pricing Hearings Add Up To Action On Pricing Transparency?

Mylan’s discussion of how the drug supply chain absorbs pricing for EpiPen raised more questions than it answered during a House Oversight Committee hearing

Related Content

Topics

UsernamePublicRestriction

Register

SC064403

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel